Natural and Induced T Regulatory Cells in Cancer
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
CD4+Foxp3+ T regulatory (Treg) cells control many facets of immune responses ranging from autoimmune diseases, to inflammatory conditions, and cancer in an attempt to maintain immune homeostasis. Natural Treg (nTreg) cells develop in the thymus and constitute a critical arm of active mechanisms of peripheral tolerance particularly to self antigens. A growing body of knowledge now supports the existence of induced Treg (iTreg) cells which may derive from a population of conventional CD4+ T cells. The fork-head transcription factor (Foxp3) typically is expressed by natural CD4+ Treg cells, and thus serves as a marker to definitively identify these cells. On the contrary, there is less consensus on what constitutes iTreg cells as their precise definition has been somewhat elusive. This is in part due to their distinct phenotypes which are shaped by exposure to certain inflammatory or "assault" signals stemming from the underlying immune disorder. The "policing" activity of Treg cells tends to be uni-directional in several pathological conditions. On one end of the spectrum, Treg cell suppressive activity is beneficial by curtailing T cell response against self-antigens and allergens thus preventing autoimmune diseases and allergies. On the other end however, their inhibitory roles in limiting immune response against pseudo-self antigens as in tumors often culminates into negative outcomes. In this review, we focus on this latter aspect of Treg cell immunobiology by highlighting the involvement of nTreg cells in various animal models and human tumors. We further discuss iTreg cells, relationship with their natural counterpart, and potential co-operation between the two in modulating immune response against tumors. Lastly, we discuss studies focusing on these cells as targets for improving anti-tumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“For advanced melanoma, it is worth mentioning that administration of humanized anti-CTLA-4, ipilimumab improved survival of patients with metastatic melanoma in a clinical trial (129).”
BackgroundControl of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 2×
“Consistent with this and other reports (16, 91, 92), we have recently identified CCR4 to be highly expressed on the majority of tumor-infiltrating Treg cells in a human melanoma study (manuscript in preparation).”
ResultUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 2×
“Other inhibitory agents produced by tumors such as IDO (105) may re-shape DCs to become tolerogenic and in turn promote induction of Foxp3+ Treg cells (106).”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435 · cited 1×
“Other tumor-derived soluble factors such as GM-CSF and VEGF may recruit or expand MDSCs which then secrete cytokines that could potentially induce Treg cells (98, 99).”
BackgroundCD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Cited by
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
“Chemokine receptors CCR4, CCR5, CCR6, and CCR10 expressed by nTreg cells are involved in their migration into the tumor microenvironment (Adeegbe and Nishikawa, 2013).”
BackgroundLineage tracking reveals dynamic relationships of T cells in colorectal cancer
Zhang, L., Yu, X., Zheng, L., Zhang, Y., Li, Y., Fang, Q., Gao, R., Kang, B., Zhang, Q., Huang, J. Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0694-x · Cited by 1,505
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue, Y., & Nishikawa, H. (2019) · Cancer Science · doi:10.1111/cas.14069 · Cited by 1,041
Self-citationMiao, Y., Zhang, Q., Lei, Q., Luo, M., Xie, G., Wang, H., & Guo, A. (2020) · Advanced Science · doi:10.1002/advs.201902880 · Cited by 973
Roles of regulatory T cells in cancer immunity
Takeuchi, Y., & Nishikawa, H. (2016) · International Immunology · doi:10.1093/intimm/dxw025 · Cited by 523
Self-citationChaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Role of tumor microenvironment in cancer progression and therapeutic strategy
Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5698 · Cited by 442
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Xu, C., Fillmore, C. M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 391
Tumor-Associated Macrophages: Implications in Cancer Immunotherapy
Petty, A. J., & Yang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2016-0135 · Cited by 363
Wang, J., Li, D., Cang, H., & Guo, B. (2019) · Cancer Medicine · doi:10.1002/cam4.2327 · Cited by 349
Xu, X. R., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 325
The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder
Maes, M., & Carvalho, A. F. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1016-x · Cited by 306
Chiang, C.-S., Lin, Y.-J., Lee, R., Lai, Y.-H., Cheng, H.-W., Hsieh, C.-H., Shyu, W.-C., & Chen, S.-Y. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0146-7 · Cited by 283
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care
Hartshorn, C. M., Bradbury, M. S., Lanza, G. M., Nel, A. E., Rao, J., Wang, A. Z., Wiesner, U. B., Yang, L., & Grodzinski, P. (2018) · ACS Nano · doi:10.1021/acsnano.7b05108 · Cited by 258
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 215
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
“Immunosuppressive regulatory T cells (Tregs) are frequently increased in cancers (58).”
BackgroundThe role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118
Nanoparticle Interactions with the Tumor Microenvironment
Huai, Y., Hossen, M. N., Wilhelm, S., Bhattacharya, R., & Mukherjee, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00448 · Cited by 113
Braga, W. M. T., da Silva, B. R., de Carvalho, A. C., Maekawa, Y. H., Bortoluzzo, A. B., Rizzatti, E. G., Atanackovic, D., & Colleoni, G. W. B. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1589-9 · Cited by 88
Chen, J., Liu, K., Luo, Y., Kang, M., Wang, J., Chen, G., Qi, J., Wu, W., Wang, B., Han, Y., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.008 · Cited by 84
Metadata
- Authors
- Adeegbe, D. O., & Nishikawa, H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 190-190
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2005654301
- Cited by
- 248
- References
- 24
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.